Jazz Pharmaceuticals Reports Q3 2026 Results with Revenue Growth and Raised Guidance
Jazz Pharmaceuticals (JAZZ) reported third-quarter 2026 revenue of $1.24 billion, a 10% year-over-year increase driven by strong performance in its oncology portfolio and Xywav sales. The company's oncology segment grew 35%, bolstered by Zepzelca and Modeyso, while Xywav net product sales rose 12% to $483 million. Despite a slight decline in Epidiolex sales due to timing of deductions, the overall financial position remains robust with $1.3 billion in operating cash flow generated year-to-date. Following these results, Jazz Pharmaceuticals raised its full-year total revenue guidance to a range of $4.775 billion to $4.85 billion. The company also announced a new $500 million share repurchase authorization following the exhaustion of its previous program. While management noted potential future headwinds from competitor launches in the lung cancer market, current momentum in rare sleep and oncology products remains strong.
Topics: oncology sales patient metrics product performance revenue growth